The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | The development of new tools to explore the biology of malignant transformation
Sandrine Roulland, PharmD, PhD, Center for Immunology of Marseille-Luminy (CIML), Marseille, France, discusses the development of new tools to explore the biology of malignant transformation, particularly in follicular lymphoma and chronic lymphocytic leukemia (CLL). She highlights the importance of epigenetic landscapes in characterizing the transition from monoclonal B-cell lymphocytosis (MBL) to CLL, suggesting that epigenetic markers are more reliable than transcriptomic markers. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The session that I shared was about developing new tools to explore the biology of malignant transformation. It was about different types of tumors, follicular lymphoma and CLL. We had a nice talk from Giovanni Tonon that explores the biology and the epigenetic landscape of the MBL that can progress into CLL and compared the differences between epigenetic landscape versus transcriptomic landscape and provided evidence that the epigenetic landscape is really a strong marker and provides better markers than the transcriptome to characterize the MBL to CLL transition...
The session that I shared was about developing new tools to explore the biology of malignant transformation. It was about different types of tumors, follicular lymphoma and CLL. We had a nice talk from Giovanni Tonon that explores the biology and the epigenetic landscape of the MBL that can progress into CLL and compared the differences between epigenetic landscape versus transcriptomic landscape and provided evidence that the epigenetic landscape is really a strong marker and provides better markers than the transcriptome to characterize the MBL to CLL transition. So we also had a nice talk from Dinis Calado who developed a mouse model of follicular lymphoma combining several genetic hits and he tried to understand what are the characteristics of therapy-resistant cells upon R-CHOP therapy. And he is really trying to decipher the biology of follicular lymphoma CPC in order to be able to target those cells and prevent eventual relapses.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
